Skip to content

The effect of Memantine in migraine patients

The effect of Memantine on migraine pain severity,mental health and quality of life in patients with migraine

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20171230038142N21
Enrollment
84
Registered
2020-09-21
Start date
2019-08-21
Completion date
Unknown
Last updated
2020-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Migraine. Migraine

Interventions

Intervention 1: Control group:In this group, there are 42 patients with migraine who use topiramate at a dose of 50 mg made by Sobhan Iranian Pharmaceutical Company. This drug is used daily for two mo

Sponsors

Esfahan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patient satisfaction Having a migraine criterion based on the International Headache Association criteria

Exclusion criteria

Exclusion criteria: History of addiction to any drug Treated with herbal medicines and other palliative medicine treatments Treated with other prophylactic drugs Treated with corticosteroids

Design outcomes

Primary

MeasureTime frame
Quality of life. Timepoint: Before and two months after the start of the intervention. Method of measurement: Headache Impact Test: HIT.;Mental Health. Timepoint: Before and two months after the start of the intervention. Method of measurement: Patient Health Question questionnaire: PHQ.;Severity of headache. Timepoint: Before and two months after the start of the intervention. Method of measurement: Visual Analogue Scale.;Duration of headache per attack. Timepoint: Before and two months after the start of the intervention. Method of measurement: Question from the patient.;Number of headaches per week. Timepoint: Before and two months after the start of the intervention. Method of measurement: Question from the patient.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFariborz Khorvash

Esfahan University of Medical Sciences

Fkhorvash@gmail.com+98 31 3668 0048

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026